Prospective Evaluation of Radiotherapy Using Magnetic Resonance Image Guided Treatment
PERMIT
1 other identifier
interventional
200
1 country
1
Brief Summary
The purpose of PERMIT is to collect information on the treatment of radiotherapy patients using a new radiotherapy machine that includes magnetic Resonance (MR) imaging (MR linac) to guide treatment. The aim is to use this information to support the introduction of MR Linac into clinical practice. PERMIT will collect details on patients treated on the MR linac plus details on their side effects and other outcomes. This information plus technical and imaging information will be combined with information from other centres using this machine. By doing so this will help us learn how best to use the MR Linac in the future and design new radiotherapy protocols
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable cancer
Started Jan 2019
Longer than P75 for not_applicable cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 31, 2018
CompletedFirst Posted
Study publicly available on registry
November 1, 2018
CompletedStudy Start
First participant enrolled
January 11, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2025
CompletedNovember 7, 2019
November 1, 2019
4.8 years
October 31, 2018
November 6, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Technical feasibility of undertaking MRL based radiotherapy at multiple clinical sites: The percentage of treatment fractions delivered successfully on the MR linac
The percentage of treatment fractions delivered successfully on the MR linac, if more than 20 % of patients (depending on treatment site) need to be treated on alternative machine or treatment protocol changed will lead to the MRL protocol at that site to be judged not feasible.
2 years
Study Arms (1)
Radiotherapy delivered on the MR Linac
EXPERIMENTALMR Guided radiotherapy treatment
Interventions
Eligibility Criteria
You may qualify if:
- Radiotherapy treatment suitable to be delivered on the MR Linac.
- Patient provides written, informed consent and/or authorization.
- Patients between the ages of 5 and under 16 years old may enter protocol with parental/guardian consent.
You may not qualify if:
- Contra-indications to MR imaging.
- Radiotherapy not suitable for delivery on the MR Linac e.g. those with extended field lengths (exceeding 20 cm).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Royal Marsden NHSFT
London, United Kingdom
MeSH Terms
Conditions
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 31, 2018
First Posted
November 1, 2018
Study Start
January 11, 2019
Primary Completion
November 1, 2023
Study Completion
November 1, 2025
Last Updated
November 7, 2019
Record last verified: 2019-11
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
Anonymised data will be shared within the academic and industrial partners. All data sharing would be dependant on appropriate data sharing agreements.